Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data
By Michael Susin
Pfizer and Valneva on Tuesday said data from a mid-stage study regarding the second booster dose from its Lyme disease vaccine candidate showed positive results.
The companies said the phase 2 study of the VLA15-221 vaccine showed a strong immune response and positive safety profile one month after the second booster dose.
The response is consistent to those reported after receiving the first booster dose, they said, showing the compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season.
Pfizer and Valneva added that the VLA15 vaccine is currently undergoing phase 3 trials, adding that there currently isn't an approved human vaccine for Lyme disease.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 03, 2024 06:28 ET (10:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks